In the recent PAR008 release PAR management claimed that there was not just cartilage preservation but growth. This is unheard of in any OA medication study.
So why is there a lack of scientific or media interest?
Why is there a lack of exuberance in the AGM on this point?
Why is there an increase in short interest?
Why would non-executive directors leave?
Why the lack of peer review that has always been promised, for a number of years?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.015(3.49%) |
Mkt cap ! $164.9M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 44.0¢ | 41.5¢ | $216.2K | 510.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12344 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 42.5¢ | 2286 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |